Merck KGaA: Stimuvax Clinical Program Temporarily Suspended
Merck KGaA announced that it has temporarily suspended the clinical program for Stimuvax® (BLP25 liposome vaccine) in all recruiting studies worldwide as a result of a suspected unexpected serious adverse reaction (SUSAR). This decision was taken in alignment with the U.S. Food and Drug Administration’s (FDA) clinical hold placed on the Investigational New Drug (IND) application for Stimuvax.
A patient participating in a Phase II exploratory clinical trial with the therapeutic cancer vaccine in patients with multiple myeloma developed encephalitis. The patient was randomized to an experimental arm of Stimuvax in combination with an intensified schedule of low-dose cyclophosphamide, which is not used in the other Stimuvax studies.
Effective immediately, the company has temporarily suspended recruitment into and treatment of patients already enrolled into the recruiting Stimuvax clinical trials. This action is a precautionary measure while the company is diligently investigating the cause of this adverse event.
The Phase III clinical program, consisting of the non-small cell lung cancer (NSCLC) studies START and INSPIRE and the breast cancer study STRIDE, is impacted as well as the other recruiting studies.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

High-speed snapshots of biomolecules - PETRA III pioneers protein serial crystallography at synchrotrons
Mbiotech to distribute Gene Bridges Recombineering Technology in Korea
BASF divests Omega-3 production plant
AMSBIO and Chondrex Cooperate On Arthritis & Inflammation Research
Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis

Atomic insights into plant growth - Researchers from Tübingen resolve how a plant steroid hormone makes plants grow
Breakthroughs in Chikungunya Research Led by A*STAR Scientists Spell New Hope for Better Treatment and Protection
Euphorbia_poisonii

Toxic agents behind Parkinson's disease seen at work for the first time - First look at how toxic protein clusters disrupt the membranes of healthy brain cells.

Nanoscale Velcro used for Molecule Transport
